Described herein is a treatment of acute respiratory distress syndrome (ARDS) using incremental dosing of nitric oxide.

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

A capsule for a heat-not-burn (HNB) aerosol-generating device may include a first heater, a second heater, and a frame sandwiched between the first heater and the second heater, and a cannabinoid-containing material. The frame may define open spaces therein and have a rigidity that is adequate to support the first heater and the second heater. The open spaces within the frame may be interconnected and sized for aerosol-permeability and capillary action.

Multistage vaporizers, such as for use in medical treatment systems, as well as related methods are described. In one example, a multistage vaporizer includes a first reservoir configured to hold a liquid and one or more pumping transducers positioned in the first reservoir. The multistage vaporizer also includes a second reservoir and one or more vaporizing transducers positioned in the second reservoir. The one or more pumping transducers positioned in the first reservoir are configured to generate and move droplets of a liquid in the first reservoir to the second reservoir, and the one or more vaporizing transducers positioned in the second reservoir are configured to create a vapor of the liquid in the second reservoir.

The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.

The invention relates to a vaping compound which is comprised of a vaporizing base which is formed from the following ingredients propylene glycol, MCT oil and vegetable glycerin, or combination of the oils, flavoring, water and one or more active ingredients.

The present invention relates to pharmaceutical composition for intranasal or pulmonary delivery, wherein the composition comprises an artemisinin derivative and optionally one or more pharmaceutically acceptable excipients. The pharmaceutical composition may be for intranasal delivery, may be in the form of a nasal spray, a solution, a suspension, nasal drops, an insufflation powder or a nasal powder, and may be suitable for delivery using a nebulizer, insufflator, powder sprayer or powder inhaler. Alternatively, the pharmaceutical composition may be for pulmonary delivery, may be in the form of an aerosol composition or a powder, and may be suitable for delivery using a metered dose inhaler (MDI) or a dry powder inhaler (DPI). The present invention also relates to processes for preparing such compositions and to the use of such compositions for the treatment of malaria.

The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.

A composition from Traditional Chinese Medicine (TCM) ingredients makes it possible to treat those infected with a virus, including, e.g., coronavirus or the flu, including but not limited to COVID-19 or Influenza A (“FluA”). Although makeable by other methods, the composition is makeable from a decoction of the TCM ingredients. Although usable for other purposes, the composition may be used to treat a patient in need of treatment for a virus, e.g., coronavirus infection, such as COVID-19 infection, or, e.g., the flu, such as FluA, by administering to the patient an effective amount of the composition.